Title : CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux.

Pub. Date : 2015 Dec 15

PMID : 26672083






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Although selumetinib did not improve survival or response, most responders had BRAF-activating mutations, and selumetinib has since demonstrated efficacy in BRAF-mutant melanoma. AZD 6244 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens